While the prescription of medicine for off-label use is legal, the FDA prohibits pharmaceutical companies from promoting these uses in any way, claiming that said companies are engaging in misbranding.
Is this regulation of pharmaceutical companies by the FDA a violation of the First Amendment? Christina Sandefur of the Goldwater Institute explores the issues surrounding off-label promotion.
As always, the Federalist Society takes no particular legal or public policy positions. All opinions expressed are those of the speaker.
Follow Christina Sandefur on Twitter @cmsandefur
[ Ссылка ]
Learn more about Christina Sandefur: [ Ссылка ]
Differing Views:
Regulatory Transparency Project: Off-Label Promotion and Free Speech in Medicine
[ Ссылка ]
The Goldwater Institute: Restoring Free Speech in Medicine
[ Ссылка ]
The University of Chicago Law Review: The Statutory Case Against Off-Label Promotion
[ Ссылка ]
Law Review: A Spoonful of Free Speech Helps the Medicine Go Down
[ Ссылка ]
Boston University Law Review: When Truth Cannot Be Presumed: The Regulation of Drug Promotion Under an Expanding First Amendment
[ Ссылка ]
